US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Binah Capital Group Inc

2.35

-0.0100-0.42%

Volume:36.64K

Turnover:87.36K

Market Cap:39.02M

PE:-20.03

High:2.46

Open:2.34

Low:2.31

Close:2.36

Loading ...

Overview Company News Filings

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Press Release: Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report

Stagwell (STGW) Unveils New SPORT BEACH 2025 Athletes and Brand Partners Including Erin Andrews, Sir Mo Farah, Chris Paul, Alex Rodriguez, George Russell, Charissa Thompson and More

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Press Release: BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue

Binah Capital Group Full Year 2024 Earnings: US$0.28 loss per share (vs US$0.43 profit in FY 2023)

Simply Wall St.

BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 Results

Press Release: Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Altice USA to Present at the 2025 New Street Research and BCG Future of Connectivity Leaders Conference

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

ImmunityBio Partner US Urology Begins Administering rBCG to Address Tice BCG Shortage

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCG/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","market":"US","secType":"STK","nameCN":"Binah Capital Group Inc","latestPrice":2.35,"timestamp":1753473600000,"preClose":2.36,"halted":0,"volume":36638,"delay":0,"floatShares":3036659,"shares":16602460,"eps":-0.117335,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"07-28 04:42:57 EDT","open":2.34,"high":2.46,"low":2.31,"amount":87359.46401,"amplitude":0.063559,"askPrice":3.03,"askSize":100,"bidPrice":1.79,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.117335,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1753709400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":2.37,"postHourTrading":{"tag":"盘后","latestPrice":2.35,"preClose":2.35,"latestTime":"19:22 EDT","volume":2,"amount":4.7,"timestamp":1753485731129},"volumeRatio":0.7308264782780368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCG\",,,,,undefined,":{"symbol":"BCG","floatShares":3036659,"roa":"-2.91%","roe":"-11.19%","lyrEps":-0.318929,"volumeRatio":0.7308264782780368,"shares":16602460,"dividePrice":0,"high":2.46,"amplitude":0.063559,"preClose":2.36,"low":2.31,"week52Low":1.71,"pbRate":"101.08","psRate":"0.23","week52High":6.55,"institutionHeld":0,"latestPrice":2.35,"eps":-0.117335,"divideRate":0,"volume":36638,"delay":0,"ttmEps":-0.117335,"open":2.34,"prevYearClose":2.94,"prevWeekClose":2.35,"prevMonthClose":2.04,"prevQuarterClose":2.04,"fiveDayClose":2.12,"twentyDayClose":2,"sixtyDayClose":2.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCG\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530175929","title":"Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175929","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175929?lang=en_us&edition=fundamental","pubTime":"2025-04-27 01:30","pubTimestamp":1745688600,"startTime":"0","endTime":"0","summary":"Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care  Bacillus Calmette-Guérin  regimen compared to SOC alone. Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-nave, high-risk non-muscle invasive bladder cancer in more than 30 years. Results have been shared with global health authorities to support potential regulatory filings. \"New bladder cancer treatment options that help reduce rates of disease recurrence or progression are long overdue. Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades,\" said Neal Shore, M.D., FACS, Medical Director for START Carolina Research Center, and lead investigator ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-sasanlimab-combination-significantly-improves-173000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGXZ57979304.SGD","BK4203","BK4534","LU0306806265.USD","LU1894683348.USD","SG9999002232.USD","LU1023059063.AUD","IE00BLSP4239.USD","CI","IE00BBT3K403.USD","BK4550","SG9999013999.USD","LU0289739699.SGD","BK4007","LU0170899867.USD","IE00BSNM7G36.USD","LU0225771236.USD","LU1066053197.SGD","LU0122379950.USD","SG9999003800.SGD","BK4097","BK4585","LU1883839398.USD","LU0985481810.HKD","SG9999011175.SGD","CR","SOC","BK4231","HR","OS","BK4135","SG9999001176.USD","BK4581","BK4588","ADC","IE0002270589.USD","LU0321505439.SGD","BK4592","BK4213","LU1059921491.USD","SG9999002224.SGD","LU1261432733.SGD","LU0456855351.SGD","IE000M9KFDE8.USD","BCG","LU0234572021.USD","BK4533","LU1057294990.SGD","PFE"],"gpt_icon":1},{"id":"2529986685","title":"CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986685","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986685?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., April 24, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer  to be presented on April 26, 2025, at a Plenary Session at the American Urological Association  Annual Meeting in Las Vegas, Nevada.About Bladder CancerMore than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases.Cretostimogene is an investigational, intravesical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-host-conference-call-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","US2Y.BOND","IE00B3QW5Z07.USD","BK4588","CG","US5Y.BOND","BOND","IE00B64PRP62.GBP","US3Y.BOND","CGON","US30Y.BOND","BK4139","US10Y.BOND","BK4218","HST","US7Y.BOND","US6M.BOND","BCG","US12M.BOND","BK4585","IE00BGHQF748.EUR","BK4135"],"gpt_icon":0},{"id":"2529502826","title":"Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502826","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502826?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 23, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer , including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2025, at 7:00 a.m. PT.TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-host-conference-call-120000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TARA","BK4218","BK4135","BK4139","HST","BK4585","IE00B66KJ199.SGD","AEIS","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4523","BK4157","BCG","IE0031619046.USD","IFN","BK4181","BK4588"],"gpt_icon":0},{"id":"2527042761","title":"Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527042761","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527042761?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:13","pubTimestamp":1744747980,"startTime":"0","endTime":"0","summary":"NEW YORK, April 15, 2025  -- Protara Therapeutics, Inc. , a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies.\"We are delighted to welcome Dr. Nicacio to the Protara team,\" said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. \"As a proven leader with deep expertise spanning all stages of drug development, his guidance and insight will be invaluable as we advance our therapeutic candidates for patients impacted by some of the most underserved cancers and rare diseases.\". Dr. Nicacio earned his Medical Degree from Faculdade de Ciencias Medicas de Minas Gerais and completed a molecular biology research fellowship at New York Blood Center. He is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4007","LENZ","BK4139","TARA","BK4135"],"gpt_icon":0},{"id":"2527413421","title":"ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413421","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413421?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including:. In Q1, the company submitted a supplemental Biologics License Application  for use of ANKTIVA plus Bacillus Calmette-Guérin  in BCG-unresponsive non-muscle invasive bladder cancer  for the indication of papillary disease.In Q2, the company submitted to the U.S. Food and Drug Administration  an Expanded Access Protocol  for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse effects of chemotherapy, radiation and checkpoint inhibitors, following authorization of a Regenerative Medicine Advanced Therapy  designation for this indication in Q1.With a permanent J-code  awarded in January 2025, ImmunityBio’s Q1 2025 ANKTIVA unit sales volume grew 150% over unit sales volume in Q4 2024.CULVER CITY, Calif., April 15, 2025----ImmunityBio, Inc. , a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-announces-fda-submissions-supplemental-120000240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","BK4585","LU1791807156.HKD","DFS","LU1861220207.SGD","BK4588","BK4139","BCG","IBRX","LU1668664300.SGD","LU0106831901.USD","LU2360107671.USD","CARE","BK4135","LU1861217088.USD","BK4211"],"gpt_icon":0},{"id":"2526954081","title":"Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526954081","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526954081?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:05","pubTimestamp":1744315500,"startTime":"0","endTime":"0","summary":"NEW YORK, April 10, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announcedthat two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer  will be featured at the upcoming American Urological Association  2025 Annual Meeting taking place fromApril 26, 2025to April 29, 2025 inLas Vegas.A copy of the abstract for the ADVANCED-2 interim analysis is now available on the AUA website. Updated safety and efficacy data, including data from patients who have reached the 12-month evaluation timepoint, will be featured during an interactive poster session on Saturday, April 26, 2025.ADVANCED-2  is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS  who are Bacillus Calmette-Guérin -unresponsive  and BCG-Nave . The BCG-Unresponsive c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-present-interim-analysis-200500382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","IE00B7SZL793.SGD","IFN","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE0031619046.USD","AEIS","BK4107","AFG","BCG","BK4135","TARA","BK4523","BK4157","BK4139"],"gpt_icon":0},{"id":"2526483373","title":"Press Release: Binah Capital Group's David Shane Recognized Among Top 5 Wealth Management CFOs by Wealth Solutions Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2526483373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526483373?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:00","pubTimestamp":1744228800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 09, 2025  -- Binah Capital Group, Inc.  , a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, proudly announces that its Chief Financial Officer , David Shane, has been named one of the Top 5 Wealth Management CFOs by Wealth Solutions Report in their annual \"CFO 5\" list. This prestigious recognition highlights CFOs who have demonstrated exceptional leadership and strategic vision in the financial services industry.The full article detailing the \"CFO 5\" list is available on the Wealth Solutions Report website here.Binah Capital Group is a financial services enterprise that owns and operates a network of industry-leading firms that empower independent financial advisors. As a national broker-dealer aggregator, Binah specializes in delivering value through its innovative hybrid-friendly model, making it an optimal platform for RIAs navigating today's complex financial landscape. Binah","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2526646553","title":"Stagwell (STGW) Unveils New SPORT BEACH 2025 Athletes and Brand Partners Including Erin Andrews, Sir Mo Farah, Chris Paul, Alex Rodriguez, George Russell, Charissa Thompson and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2526646553","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526646553?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:01","pubTimestamp":1744203660,"startTime":"0","endTime":"0","summary":"Registration now open for SPORT BEACH 2025 at sportbeach.com. NEW YORK, April 9, 2025 /PRNewswire/ -- Stagwell , the challenger network built to transform marketing, today launched registration for SPORT BEACH 2025 at sportbeach.com and announced an expanded lineup of athletes and brand partners.Notable new additions to this year's roster include sports broadcaster Erin Andrews, long-distance runner and Olympic Gold Medalist Sir Mo Farah, NBA legend Chris Paul, MLB All-Star Alex Rodriguez, and George Russell, Mercedes-AMG PETRONAS Formula One Team driver, who will participate in featured programming throughout the week.Back in its third year, SPORT BEACH will serve as the premiere destination for sport at the Cannes Lions International Festival of Creativity  from June 16-19, 2025.Chris Paul  - Chris Paul is a legendary NBA superstar, known for his competitive spirit an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/stagwell-stgw-unveils-sport-beach-130100662.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stagwell-stgw-unveils-sport-beach-130100662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","SG9999015978.USD","SG9999015986.USD","LU0868494708.USD","BK4585","IE00BVYPNQ40.USD","LU1035775433.USD","BK4605","GB00BDT5M118.USD","BK4527","BK4609","LU1261432733.SGD","SG9999001424.SGD","LU1069344957.HKD","BK4512","BCG","LU1046421795.USD","BK4009","BK4534","LU1119994496.HKD","MMAT","BK4612","STGW","BK4575","LU1169590202.USD","BK4515","IE00BGHQDM52.EUR","LU0348723411.USD","DGE.UK","LU0942090050.USD","LU1917777945.USD","BK4543","LU0868494617.USD","BK4598","SG9999015945.SGD","SG9999015952.SGD","LU0061475181.USD","BK4141","IE00BSNM7G36.USD","BK4588","DEO","BK4573","LU1169589451.USD","BK4532","BK4559","LU1823568750.SGD","LU0079474960.USD","IE00BMPRXR70.SGD"],"gpt_icon":1},{"id":"2524205095","title":"enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205095","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205095?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"BOSTON & MONTREAL, April 04, 2025----enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price of the Company's common shares on April 2, 2025, the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the employee’s employment commencement date and the remainder vesting in equal amounts monthly for three years thereafter, subject to the employee’s continued service as an employee of, or other service provider to, the Company through the applicable vesting dates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/engene-reports-inducement-grants-under-120000127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","ENGNW","BCG","BK4585","LU2210149790.SGD","NDAQ","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","ENGN","IE00B64PRP62.GBP",".IXIC","BK4588","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2524411586","title":"Press Release: BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2524411586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524411586?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:01","pubTimestamp":1743613260,"startTime":"0","endTime":"0","summary":"BCG CEO Christoph Schweizer Reelected to a Second Term as Firm Achieves 10% Growth in 2024 and Record Revenue. BOSTON, April 2, 2025 /PRNewswire/ -- Boston Consulting Group  today announced the reelection of CEO Christoph Schweizer to a second four-year term, in a direct vote of BCG's more than 2,000 managing directors and partners.Since assuming the CEO role in 2021, Schweizer has driven BCG's growth, expanding BCG's consulting team every year. His second term begins on October 1, 2025.BCG is delivering major AI-driven transformation programs with some of the world's biggest companies, including L'Oréal, BMW, IBM and New York Life.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG"],"gpt_icon":0},{"id":"2524980495","title":"Binah Capital Group Full Year 2024 Earnings: US$0.28 loss per share (vs US$0.43 profit in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524980495","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524980495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:59","pubTimestamp":1743595178,"startTime":"0","endTime":"0","summary":"This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGM:BCG Earnings and Revenue History April 2nd 2025. All figures shown in the chart above are for the trailing 12 month  period. Binah Capital Group shares are down 2.9% from a week ago.Don't forget that there may still be risks. For instance, we've identified   2 warning signs for Binah Capital Group   you should be aware of.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/binah-capital-group-full-2024-115938454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCGWW","BCG"],"gpt_icon":0},{"id":"2524061999","title":"BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524061999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524061999?lang=en_us&edition=fundamental","pubTime":"2025-04-01 06:39","pubTimestamp":1743460797,"startTime":"0","endTime":"0","summary":"BRIEF-Binah Capital Group Reports Fourth Quarter And Full Year 2024 ResultsMarch 31 (Reuters) - Binah Capital Group Inc BCG.O:BINAH CAPITAL GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTSBINAH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUAB7RR1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BCG"],"gpt_icon":0},{"id":"2524848972","title":"Press Release: Binah Capital Group Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524848972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524848972?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:15","pubTimestamp":1743452100,"startTime":"0","endTime":"0","summary":"- Grew Total Revenue 8% Year-over-Year to $45 Million in the Fourth Quarter 2024 -. - Assets Under Management  Increased 13% Year-over-Year to $27 Billion -. - GAAP Net Loss of $1.1 Million in the Fourth Quarter -. - Grew Adjusted EBITDA(*) 43% Year-Over-Year to $2.0 Million in the Fourth Quarter -. \"As we celebrate the one-year anniversary of our successful public listing, we're pleased to deliver our 2024 fourth quarter results,\" stated Craig Gould, Chief Executive Officer of Binah Capital Group. \"Beyond our solid financial performance, we've accomplished several key milestones over the past year: closing of the business combination, forming Binah Capital Group, Inc. and listing on the NASDAQ, successful recruiting efforts, significantly reducing our cost of funding through the successful refinancing of our senior credit facility at favorable terms, and maintaining a mature and stable business despite ongoing market volatility.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","BK4135"],"gpt_icon":0},{"id":"2523456589","title":"CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456589","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456589?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052232/0/en/CG-Oncology-to-Participate-in-the-120th-American-Urological-Association-Annual-Meeting-with-a-Series-of-Key-Presentations-and-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","IE00BGHQF748.EUR","BK4117","BK4139","AFG","BCG","BK4135","IE00B3QW5Z07.USD","BK4107","IE00B64PRP62.GBP","CGON"],"gpt_icon":0},{"id":"2522430524","title":"Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522430524","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522430524?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":"- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin -Unresponsive Non-Muscle Invasive Bladder Cancer  -. - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Nave  and BCG-Exposed  NMIBC -. - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress -. IRVINE, Calif., March 28, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business updates.Any Time in High-Risk  BCG-Unresponsive NMIBC with carcinoma in situ. reached but exceeds 28 months as of the data cutoff of Januar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","US30Y.BOND","US7Y.BOND","US10Y.BOND","BK4203","LU1261432733.SGD","BK4588","IE00B19Z3B42.SGD","HR","LU0058720904.USD","BK4225","US5Y.BOND","IE00B64PRP62.GBP","US6M.BOND","BK4161","BK4196","LU1059921491.USD","US3Y.BOND","BK4135","CR","CGON","BK4585","IE00B19Z3581.USD","BK4139","IE0002270589.USD","IE00BSNM7G36.USD","CG","LU0289739699.SGD","CI","BCG","US12M.BOND","LU0868494617.USD","US2Y.BOND"],"gpt_icon":0},{"id":"2521747112","title":"Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747112","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747112?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post creto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047782/0/en/Cretostimogene-Grenadenorepvec-Data-Continues-to-Demonstrate-Best-in-Class-Durability-of-Response-as-well-as-Consistent-and-Compelling-Safety-and-Efficacy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON","BK4161","BK4135","BCG","CR"],"gpt_icon":0},{"id":"2521746200","title":"Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746200","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746200?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047703/0/en/Positive-Data-from-Phase-1-Trial-of-Bel-sar-in-Patients-with-Non-Muscle-Invasive-Bladder-Cancer-NMIBC-Presented-at-the-40th-Annual-European-Association-of-Urology-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","BCG","BK4531","LU0359202008.SGD","BK4571","BK4097","IE00BYQNZ168.SGD","BK4548","LU0359201612.USD","BK4526","01698","BK4565","BK4108","BK4552","BK4563","SG9999011746.SGD","BK4509","LU1023057109.AUD","BK4139","LU2039709279.SGD","BK4135","IE00BYTNYN87.SGD","IE00B12V2V27.USD","TLS","BK4535"],"gpt_icon":1},{"id":"2521423255","title":"Altice USA to Present at the 2025 New Street Research and BCG Future of Connectivity Leaders Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521423255","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521423255?lang=en_us&edition=fundamental","pubTime":"2025-03-22 02:47","pubTimestamp":1742582820,"startTime":"0","endTime":"0","summary":"NEW YORK, March 21, 2025----Altice USA  today announces that Dennis Mathew, Chairman and CEO, will present at the New Street Research and BCG Future of Connectivity Leaders Conference on Wednesday, March 26, 2025, at 11:35 a.m. Eastern Time. A live webcast will be available online on the Altice USA investor relations website or by following this link.Date: Wednesday, March 26, 2025Time: 11:35 a.m. Eastern TimePresenter: Dennis Mathew, Chairman & CEO. About Altice USAAltice USA  is one of the largest broadband communications and video services providers in the United States, delivering broadband, video, mobile, proprietary content and advertising services to approximately 4.6 million residential and business customers across 21 states through its Optimum brand. We operate Optimum Media, an advanced advertising and data business, which provides audience-based, multiscreen advertising solutions to local, regional and national businesses and advertising clients. We also operate News 12, wh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/altice-usa-present-2025-street-184700758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATUS","BK4135","BK4561","BCG","BK4100"],"gpt_icon":0},{"id":"2520183637","title":"Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2520183637","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520183637?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:00","pubTimestamp":1742385600,"startTime":"0","endTime":"0","summary":"Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice Conference. Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025. NEW YORK, March 19, 2025  -- Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support , will be featured during an oral session at the American Society for Parenteral and Enteral Nutrition  2025 Nutrition Science & Practice Conference, taking place March 22 through March 25, 2025 in Columbus, Ohio.The Company plans to initiate THRIVE-3, a registrational Phase 3 clinical trial, in the first half of 2025. THRIVE-3 is a seamless Phase 2b/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protara-therapeutics-announces-encore-presentation-120000672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["THAC","TARA","LENZ","BK4139","BK4135","BCG"],"gpt_icon":0},{"id":"2519323588","title":"ImmunityBio Partner US Urology Begins Administering rBCG to Address Tice BCG Shortage","url":"https://stock-news.laohu8.com/highlight/detail?id=2519323588","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519323588?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:35","pubTimestamp":1741872914,"startTime":"0","endTime":"0","summary":"ImmunityBio  said Thursday that US Urology Partners has begun administering its recombinant Bacillus Calmette-Guerin, or rBCG, in the US as part of an effort to address a shortage of Tice BCG.The company said the shortage of Tice BCG is a \"significant impediment\" to treating bladder cancer.ImmunityBio said the US Food and Drug Administration recently authorized ImmunityBio's Expanded Access Program for rBCG, and 60 urology centers are preparing to launch the treatment.The company said it is working with the Serum Institute of India to produce rBCG.Price: 2.84, Change: -0.03, Percent Change: -1.05","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","BCG","BK4139","IBRX"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":102,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCG\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCG\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCG","date":"2025-07-25","current":-20.113863,"percent":0.143322,"low":-94.684933,"twenty":-19.092292,"median":-11.268602,"eighty":-7.603246,"high":216.897522,"avg":-0.238082,"sd":54.425094,"marketCap":39181805},"quantilePoints":[{"date":"2024-04-12","current":47.846282,"twenty":47.314657,"median":50.799756,"eighty":52.276493,"marketCap":133339024},{"date":"2024-04-19","current":40.132439,"twenty":41.297957,"median":46.73873,"eighty":50.917895,"marketCap":111841925},{"date":"2024-04-26","current":203.935518,"twenty":44.420253,"median":50.799756,"eighty":187.977853,"marketCap":116447181},{"date":"2024-05-03","current":181.468046,"twenty":45.542573,"median":118.644354,"eighty":199.211588,"marketCap":103618254},{"date":"2024-05-10","current":158.424485,"twenty":47.403261,"median":158.424485,"eighty":194.026786,"marketCap":90460381},{"date":"2024-05-17","current":135.380923,"twenty":48.08256,"median":150.76106,"eighty":191.347973,"marketCap":77302507},{"date":"2024-05-24","current":216.897522,"twenty":50.268131,"median":142.815352,"eighty":191.347973,"marketCap":123848485},{"date":"2024-05-31","current":-70.098677,"twenty":46.96024,"median":139.70159,"eighty":188.726768,"marketCap":145945446},{"date":"2024-06-07","current":-77.180156,"twenty":40.710114,"median":130.655552,"eighty":184.646906,"marketCap":160689084},{"date":"2024-06-14","current":-52.991736,"twenty":-57.718026,"median":121.266741,"eighty":182.34255,"marketCap":110328794},{"date":"2024-06-21","current":-39.863152,"twenty":-52.943996,"median":66.796341,"eighty":180.865278,"marketCap":82995083},{"date":"2024-06-28","current":-46.865063,"twenty":-56.142596,"median":53.605557,"eighty":179.659743,"marketCap":97573062},{"date":"2024-07-05","current":-45.194153,"twenty":-52.896255,"median":49.470693,"eighty":176.203209,"marketCap":94094226},{"date":"2024-07-12","current":-42.966272,"twenty":-51.448132,"median":45.631177,"eighty":169.370177,"marketCap":89455779},{"date":"2024-07-15","current":-46.626362,"twenty":-50.795682,"median":45.409667,"eighty":167.641909,"marketCap":97076086},{"date":"2024-08-02","current":-31.986002,"twenty":-50.143231,"median":45.188156,"eighty":165.913642,"marketCap":66594857},{"date":"2024-08-09","current":-28.166778,"twenty":-49.363473,"median":40.613835,"eighty":159.576663,"marketCap":58643232},{"date":"2024-08-16","current":-20.272151,"twenty":-47.35838,"median":-24.029285,"eighty":158.424485,"marketCap":59802844},{"date":"2024-08-23","current":-19.247598,"twenty":-46.674102,"median":-19.602159,"eighty":156.120128,"marketCap":56780413},{"date":"2024-08-30","current":-19.866672,"twenty":-46.24444,"median":-19.585275,"eighty":147.891273,"marketCap":58606683},{"date":"2024-09-06","current":-18.302664,"twenty":-45.957998,"median":-19.585275,"eighty":144.080444,"marketCap":53992860},{"date":"2024-09-13","current":-15.251751,"twenty":-45.448768,"median":-19.106899,"eighty":140.947095,"marketCap":44992666},{"date":"2024-09-20","current":-16.883858,"twenty":-45.194153,"median":-18.403405,"eighty":138.834001,"marketCap":49807380},{"date":"2024-09-27","current":-18.009448,"twenty":-45.194153,"median":-18.156337,"eighty":136.530797,"marketCap":53127872},{"date":"2024-10-04","current":-14.801515,"twenty":-45.098673,"median":-18.009448,"eighty":129.710478,"marketCap":43664469},{"date":"2024-10-11","current":-15.139192,"twenty":-44.271652,"median":-17.794742,"eighty":123.304944,"marketCap":44660617},{"date":"2024-10-18","current":-13.732204,"twenty":-43.642912,"median":-16.883858,"eighty":121.209133,"marketCap":40510002},{"date":"2024-10-25","current":-11.706141,"twenty":-43.204974,"median":-16.377341,"eighty":95.05469,"marketCap":34533116},{"date":"2024-10-31","current":-12.147373,"twenty":-41.725024,"median":-16.067805,"eighty":68.991477,"marketCap":35834749},{"date":"2024-11-08","current":-12.325216,"twenty":-38.781038,"median":-15.870826,"eighty":54.048578,"marketCap":36359387},{"date":"2024-11-15","current":-19.641554,"twenty":-35.089122,"median":-15.983385,"eighty":51.154173,"marketCap":57942585},{"date":"2024-11-22","current":-9.482521,"twenty":-31.222157,"median":-15.814546,"eighty":49.736506,"marketCap":41174100},{"date":"2024-11-29","current":-9.867391,"twenty":-29.805862,"median":-15.758267,"eighty":48.08256,"marketCap":42834346},{"date":"2024-12-06","current":-9.217214,"twenty":-28.707835,"median":-15.561288,"eighty":47.403261,"marketCap":40011928},{"date":"2024-12-13","current":-11.205991,"twenty":-28.548701,"median":-15.251751,"eighty":45.542573,"marketCap":48645207},{"date":"2024-12-20","current":-8.873003,"twenty":-28.103124,"median":-15.039858,"eighty":44.420253,"marketCap":38517707},{"date":"2024-12-27","current":-11.66494,"twenty":-27.84851,"median":-14.773376,"eighty":41.348639,"marketCap":50637503},{"date":"2025-01-03","current":-10.555814,"twenty":-27.84851,"median":-14.407558,"eighty":41.145913,"marketCap":45822789},{"date":"2025-01-10","current":-10.364586,"twenty":-27.132405,"median":-13.712083,"eighty":40.517556,"marketCap":44992666},{"date":"2025-01-17","current":-9.599672,"twenty":-25.795677,"median":-13.338247,"eighty":11.509386,"marketCap":41672174},{"date":"2025-01-24","current":-9.561426,"twenty":-24.74539,"median":-12.325216,"eighty":-7.572649,"marketCap":41506150},{"date":"2025-01-31","current":-8.069843,"twenty":-22.526431,"median":-12.059139,"eighty":-7.572649,"marketCap":35031190},{"date":"2025-02-07","current":-8.299318,"twenty":-20.109959,"median":-11.84684,"eighty":-7.649141,"marketCap":36027338},{"date":"2025-02-14","current":-7.955106,"twenty":-19.799137,"median":-11.755302,"eighty":-7.809773,"marketCap":34533116},{"date":"2025-02-21","current":-7.534404,"twenty":-19.697834,"median":-11.685541,"eighty":-7.672088,"marketCap":32706846},{"date":"2025-02-28","current":-10.976517,"twenty":-19.697834,"median":-11.593582,"eighty":-7.542053,"marketCap":47649060},{"date":"2025-03-07","current":-8.567038,"twenty":-19.686578,"median":-11.300169,"eighty":-7.572649,"marketCap":37189510},{"date":"2025-03-14","current":-7.381421,"twenty":-19.641554,"median":-11.255905,"eighty":-7.572649,"marketCap":32042747},{"date":"2025-03-21","current":-7.151947,"twenty":-19.630298,"median":-11.225114,"eighty":-7.350824,"marketCap":31046600},{"date":"2025-03-28","current":-7.687386,"twenty":-19.585275,"median":-11.1295,"eighty":-7.412018,"marketCap":33370944},{"date":"2025-04-04","current":-7.242195,"twenty":-19.569517,"median":-10.842657,"eighty":-7.32062,"marketCap":33038895},{"date":"2025-04-11","current":-6.987445,"twenty":-19.454706,"median":-10.555814,"eighty":-7.159596,"marketCap":31876723},{"date":"2025-04-17","current":-7.496946,"twenty":-19.247598,"median":-10.43842,"eighty":-7.190192,"marketCap":34201067},{"date":"2025-04-25","current":-8.006447,"twenty":-18.9662,"median":-10.135111,"eighty":-7.242195,"marketCap":36525412},{"date":"2025-05-02","current":-8.388573,"twenty":-18.90992,"median":-9.982129,"eighty":-7.266684,"marketCap":38268670},{"date":"2025-05-09","current":-7.860875,"twenty":-18.572243,"median":-9.867391,"eighty":-7.314981,"marketCap":35861313},{"date":"2025-05-16","current":-8.406769,"twenty":-18.572243,"median":-9.867391,"eighty":-7.343175,"marketCap":38351682},{"date":"2025-05-23","current":-20.369548,"twenty":-19.247598,"median":-9.867391,"eighty":-7.381421,"marketCap":39679879},{"date":"2025-05-30","current":-18.835439,"twenty":-19.522241,"median":-9.943883,"eighty":-7.381421,"marketCap":36691436},{"date":"2025-06-06","current":-18.153613,"twenty":-19.522241,"median":-10.135111,"eighty":-7.442614,"marketCap":35363239},{"date":"2025-06-13","current":-17.471788,"twenty":-19.299375,"median":-10.401503,"eighty":-7.489139,"marketCap":34035043},{"date":"2025-06-20","current":-17.216103,"twenty":-19.209964,"median":-10.536691,"eighty":-7.518782,"marketCap":33536969},{"date":"2025-06-27","current":-17.045647,"twenty":-19.179762,"median":-10.708797,"eighty":-7.533978,"marketCap":33204920},{"date":"2025-07-03","current":-17.045647,"twenty":-19.092292,"median":-11.091254,"eighty":-7.534404,"marketCap":33204920},{"date":"2025-07-11","current":-16.789962,"twenty":-18.947987,"median":-11.20309,"eighty":-7.549702,"marketCap":32706846},{"date":"2025-07-18","current":-18.153613,"twenty":-18.916369,"median":-11.255905,"eighty":-7.572649,"marketCap":35363239},{"date":"2025-07-25","current":-20.113863,"twenty":-19.092292,"median":-11.268602,"eighty":-7.603246,"marketCap":39181805}],"updateTime":1753656409798}}}